CMG Pharmaceutical Co., Ltd. (KOSDAQ:058820)
South Korea
· Delayed Price · Currency is KRW 1,804.00
+14.00 (0.78%)
Apr 29, 2026, 3:30 PM KST
CMG Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -10,077 | 2,695 | 6,455 | -388.14 | 3,051 | Upgrade
|
| Depreciation & Amortization | 3,082 | 3,346 | 2,558 | 2,284 | 2,106 | Upgrade
|
| Loss (Gain) From Sale of Assets | -10.2 | 11 | 4.09 | 22.76 | -0.5 | Upgrade
|
| Asset Writedown & Restructuring Costs | 5,165 | 1,133 | 241.97 | 329 | 91.25 | Upgrade
|
| Loss (Gain) From Sale of Investments | -1,047 | 5,909 | -35.58 | 4,145 | -534.01 | Upgrade
|
| Loss (Gain) on Equity Investments | 1,363 | 1,086 | -1,134 | 3,807 | - | Upgrade
|
| Stock-Based Compensation | 40.22 | 57.09 | 60.29 | 26.64 | 439.08 | Upgrade
|
| Provision & Write-off of Bad Debts | 954.46 | 468.43 | 10.6 | -219.54 | 213.58 | Upgrade
|
| Other Operating Activities | 4,449 | -5,046 | 3,436 | -764.94 | 2,545 | Upgrade
|
| Change in Accounts Receivable | -4,357 | -8,212 | -2,864 | -1,463 | -3,185 | Upgrade
|
| Change in Inventory | -6,987 | -4,677 | -497.72 | -8,857 | -939.47 | Upgrade
|
| Change in Accounts Payable | -2,432 | 2,816 | -2,049 | 6,207 | 165.71 | Upgrade
|
| Change in Other Net Operating Assets | -1,164 | 703.02 | -2,248 | -190.64 | -1,129 | Upgrade
|
| Operating Cash Flow | -11,020 | 290.09 | 3,938 | 4,938 | 2,823 | Upgrade
|
| Operating Cash Flow Growth | - | -92.63% | -20.24% | 74.88% | 218.39% | Upgrade
|
| Capital Expenditures | -29,630 | -28,098 | -12,384 | -8,382 | -8,176 | Upgrade
|
| Sale of Property, Plant & Equipment | 80.94 | - | 1.5 | - | 0.5 | Upgrade
|
| Cash Acquisitions | - | - | -3,129 | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -3,011 | -3,150 | -2,861 | -1,926 | -3,474 | Upgrade
|
| Investment in Securities | 46,449 | -2,616 | -16,834 | 3,485 | -58,948 | Upgrade
|
| Other Investing Activities | -328.35 | 164.73 | -45 | 49 | 1.9 | Upgrade
|
| Investing Cash Flow | 13,626 | -55,743 | -28,221 | -10,868 | -70,596 | Upgrade
|
| Short-Term Debt Issued | 1,500 | - | - | - | - | Upgrade
|
| Long-Term Debt Issued | - | 56,785 | 21,500 | 6,000 | - | Upgrade
|
| Total Debt Issued | 1,500 | 56,785 | 21,500 | 6,000 | - | Upgrade
|
| Long-Term Debt Repaid | -246.87 | -294.31 | -404.51 | -371.85 | -113.56 | Upgrade
|
| Net Debt Issued (Repaid) | 1,253 | 56,491 | 21,095 | 5,628 | -113.56 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 72,992 | Upgrade
|
| Common Dividends Paid | - | - | -29.28 | - | - | Upgrade
|
| Other Financing Activities | -307.34 | 292.32 | -0 | -0 | - | Upgrade
|
| Financing Cash Flow | 945.79 | 56,783 | 21,066 | 5,628 | 72,878 | Upgrade
|
| Foreign Exchange Rate Adjustments | -17.18 | 15.12 | 3.07 | -0.94 | 0.44 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -0 | - | 0 | 0 | - | Upgrade
|
| Net Cash Flow | 3,535 | 1,346 | -3,213 | -303.22 | 5,106 | Upgrade
|
| Free Cash Flow | -40,650 | -27,808 | -8,446 | -3,444 | -5,352 | Upgrade
|
| Free Cash Flow Margin | -38.63% | -28.06% | -8.99% | -4.19% | -9.13% | Upgrade
|
| Free Cash Flow Per Share | -282.37 | -51.60 | -60.81 | -24.80 | -44.03 | Upgrade
|
| Cash Interest Paid | 1,049 | 870.52 | 457.46 | 194.75 | - | Upgrade
|
| Cash Income Tax Paid | 483.41 | 41.22 | 687.44 | 107.61 | 183.95 | Upgrade
|
| Levered Free Cash Flow | -42,983 | -33,024 | 1,460 | - | -10,906 | Upgrade
|
| Unlevered Free Cash Flow | -41,002 | -31,454 | 1,509 | - | -10,900 | Upgrade
|
| Change in Working Capital | -14,940 | -9,370 | -7,658 | -4,304 | -5,087 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.